An interventional study of urine intestinal permeability test or lactulose/mannitol test and Blood test in Irritable Bowel Syndrome (IBS), sponsored by University Hospital, Rouen. Not yet recruiting at 1 site in France. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-13.
Sponsored by University Hospital, Rouen · Not applicable, Interventional, and Diagnostic
Among 12 studies in Irritable Bowel Syndrome by University Hospital, Rouen — 5 open to participants now, 5 under way, none of them phase 3. Irritable Bowel Syndrome · University Hospital, Rouen.
Among the 12 studies in Irritable Bowel Syndrome by University Hospital, Rouen, this one is the only one that started in 2026, is one of 7 with no phase, and was the 12th registered.
1,116 studies on the registry are indexed under Irritable Bowel Syndrome; 208 are open to participants now.
This study's planned enrollment of 60 is below the median of 70 across 896 interventional studies indexed under Irritable Bowel Syndrome.
Browse Irritable Bowel Syndrome studies →5 of the 12 studies in Irritable Bowel Syndrome by University Hospital, Rouen are open now, in 1 country. Each count lists the studies.
Of the 126 Irritable Bowel Syndrome studies recruiting now, 33 (26%) set no upper age limit and 83 (66%) stop at 75 or younger; 18 take children under 18; 28 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →12 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2026.
Median enrollment 60 across the 9 interventional studies, 600 across the 3 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
University Hospital, Rouen is the lead sponsor of 418 studies on the registry; 106 are open to participants now.
2 of the studies in Irritable Bowel Syndrome by University Hospital, Rouen that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07039747University Hospital, RouenEffectiveness of a Dietary Supplement in Irritable Bowel Syndrome | 2027-02 |
| NCT07337707University Hospital, RouenNew Microbiota-endocrine Axis in Fructose Malabsorption-caused Visceral Hypersensitivity in Irritable Bowel Syndrome. | 2027-08 |
Among the 12 studies in Irritable Bowel Syndrome by University Hospital, Rouen, from their registry updates:
Nothing recorded among them since 2026-09-25.
Irritable bowel syndrome (IBS) affects around 4% of the general population and remains the most common functional bowel disorder. It is defined by the Rome criteria as the presence of abdominal pain associated with transit disorders. The impact on quality of life and the associated costs make it a public health problem.
Visceral hypersensitivity is one of the functional markers of the disease and plays a part in the genesis of symptoms. It could therefore also be a therapeutic target to be explored. Diet and the intestinal microbiota are also part of the recognised pathophysiological mechanisms of this disease. Carbohydrates malabsorbed by the intestine are metabolised by the microbiota, which may contribute to the genesis of symptoms. Among these carbohydrates, fructose appears to be of particular interest. Its absorption capacity is limited, yet fructose consumption is increasing. Fructose malabsorption at a dose of 25 g is present in 22% of IBS patients. Fructose malabsorption is also associated with visceral hypersensitivity. However, the mechanism of this association remains unknown. In models of malabsorbed mice with visceral hypersensitivity, an increase in cholecystokinin was found in the terminal ileum and cecum, suggesting a potential role for this hormone in this model of IBS. However, the underlying mechanism remains poorly understood.
The objective is to determine if microbiota signature is specific of visceral hypersensitivity associated with fructose malabsorption in IBS patients.
60 patients with IBS will be included in the study in 4 groups:
All patients will filled validated questionnaires and 4-days food diary. They will also have a urinary permeability test (lactulose/mannitol test) and collected stools samples for microbiota analysis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For all groups:
Regulatory criteria :
For the IBS group with fructose malabsorption and visceral (named group of interest, MalF-HyperSens) (1):
For the IBS group with fructose malabsorption and without visceral hypersensitivity (known as the MalF-NormoSens group) (2):
For the IBS group without fructose malabsorption and visceral hypersensitivity (named NormoF-HyperSens group) (3):
For the IBS group without fructose malabsorption or visceral hypersensitivity (called the NormoF-NormoSens group) (4):
Exclusion Criteria:
Regulatory criteria :
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with IBS with fructose malabsorption and with visceral hypersensitivity
Biological: urine intestinal permeability test or lactulose/mannitol test · Biological: Blood test · Other: food diary · Other: stool samples · Other: Microbiota analysis
Patients with IBS with fructose malabsorption and without hypersensitivity
Biological: urine intestinal permeability test or lactulose/mannitol test · Biological: Blood test · Other: food diary · Other: stool samples · Other: Microbiota analysis
Patients with IBS without fructose malabsorption and with visceral hypersensitivity
Biological: urine intestinal permeability test or lactulose/mannitol test · Biological: Blood test · Other: food diary · Other: stool samples · Other: Microbiota analysis
Patients with IBS without fructose malabsorption and without visceral hypersensitivity
Biological: urine intestinal permeability test or lactulose/mannitol test · Biological: Blood test · Other: food diary · Other: stool samples · Other: Microbiota analysis
Patients will be required to fast for 12 hours and, after emptying their bladder, patients will be asked to drink 100 mL of water containing 10 g of lactulose and 5 g of mannitol. At the patient's inclusion visit, and before the test at the V1 follow-up visit, the patient will be given an explanation with recommendations on their food intake in the 24 hours before and 24 hours during the test (urine collection). Patients will be asked not to drink for 2 hours and not to eat for 5 hours after taking the lactulose and mannitol. An exhaustive urine collection will then be carried out at the patient's home over the 24 hours following the intake of the sugars. The 24-hour urine will be collected in a plastic 24-hour urine container suitable for hospital use. This urine collection will be brought back for visit 2 the following day. On receipt of the urine, the volume of urine will be noted and the appearance of the urine recorded and stored before analysis.
A fasting blood sample will be taken in 1 x 4ml EDTA-Aprotinin tube on the morning of the urine test (V1 follow-up visit). The tube will be centrifuged within 15 minutes at 4°C and then aliquoted into 3 x 500μL tubes which will be immediately frozen at -80°C for storage in a biocollection with a view to later measuring gastrointestinal peptides such as CCK, neurotensin and GLP-1.
On the day of inclusion, all patients were given a food diary to fill in. They will have to fill it in over a period of 4 days, including 1 weekend day. They will be asked to note down all the food they eat during this period, as well as the quantities. The diary will be collected at the V1 visit and will then be analysed by a dietician, who will assess the average daily consumption of fructose in g/d (total fructose consumption, consumption of fructose in excess of glucose, dietary origin of fructose).
All patients will have their stools collected. Patients will have their stool collected at home using a collector given to them at the inclusion visit. They will have to bring back the stool within 6 hours for preparation and storage at -80°C.
Stools will be used to analyse the composition of the intestinal microbiota by sequencing amplicons from the V3-V4 region of bacterial 16S rRNA.
microbiota analysis
16S RNA gene sequencing
Time frame: from enrollment up to 18 months
metabolites analysis
Mass spectrometry-based metabolomics
Time frame: from enrollment up to 18 months
Intestinal permeability
lactulose-mannitol test
Time frame: from enrollment up to 18 months
low grade inflammation
fecal calprotectin
Time frame: from enrollment up to 18 months
fructose consumption
delay fructose consumption (g/D)
Time frame: from enrollment up to 18 months
IBS severity
IBS-SSS
Time frame: from enrollment up to 18 months
Stool consistency
Bristol stool form
Time frame: from enrollment up to 18 months
anxiety
STAI
Time frame: from enrollment up to 18 months
psychological distress
HAD
Time frame: from enrollment up to 18 months
impact on quality of life
IBSQOL
Time frame: from enrollment up to 18 months
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Feb 2026; primary completion for Aug 2027, 18 months later.
Of 305 non-industry interventional studies with no phase under Irritable Bowel Syndrome, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 40. This study's planned 18 months is below that.
Counting every sponsor, half of 357 studies reached it within 19 months; a quarter within 9 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.